NEW YORK, June 19, 2017 /PRNewswire/ -- Highlights
Advertisement
- The global prostate cancer therapeutics market is expected to reach USD 12.0 billion by 2025, according to a new report by Grand View Research, Inc.
- According to the American Cancer Society, approximately 1 in 7 men will be diagnosed with prostate cancer in their lifetime. As per Cancer Research, a government institute, in the UK, 46,690 new cases of prostate cancer were diagnosed out of which 11,287 patients died in 2014.
- Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection.
- Early detection helps in quick and on time treatment and assists in deciding treatment regimens. In addition, major players including Astella, Inc., Sanofi, Dendreon Corporation, AstraZeneca, and Johnson & Johnson are focusing on development of effective and safe therapeutic products to treat tumor.
- As a result, generic products are anticipated to penetrate the market. All these factors together are expected to propel growth.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/prostate-cancer-therapeutics-market-is-expected-to-reach-usd-120-billion-by-2025-300476340.html
SOURCE Reportlinker